Genentech ML42439 (myTACTIC) MSI-h

myTACTIC: An open-label Phase II study evaluating targeted therapies in patients who have advanced solid tumors with genoic alterations or protein expression patterns predictive of response: Atezolizumab plus chemotherapy in patients with TMB-H/MSI-H/dMMR-positive tumors

NCT04632992

Any: Lung, Breast, Colon, Prostate, Small Cell lung, thyroid, head and neck, HNSCC, liver, pancreas, endometrial, cervical, ovarian, skin, melanoma, leukemia, lymphoma, urothelial (bladder), kidney (RCC), myeloma, gastric, small bowel,

Stage 4

Metastatic/Palliative

Any, but cannot have had prior anti-PD-1 or anti-PD-L1

Atezoliumab + chemotherapy (investigators choice- capecitabine, paclitaxel, or docetaxel)

PD-L1 inhibitor + chemotherapy

Genentech, Inc.

Phase 2

Closed to Accrual

• Histologically or cytologically confirmed advanced unresectable or metastatic solid malignancy
• Positive biomarker results from a CLIA certified lab, either tissue or blood sample
• Microsatellite instability high (MSI-h) or deficient mismatch repair dMMR
• No prior treatment with anti-PD1 or anti-PD-L1 agents
• ECOG PS 0-2
• No symptomatic CNS metastases
• No known HIV/HBV/HCV
• No other malignancy within 3 years of study
• No prior treatment with crizotinib
• No active autoimmune disease

• Primary-
  • ORR
• Secondary
  • PFS
  • DoR
  • OS
  • PFS at various time points
  • DCR
  • Safety

_

_

MSI-h or dMMR

No